FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554054155> ?p ?o ?g. }

• W2554054155 abstract "Abstract Abstract 4310 Introduction: T cell lymphoid malignancies are associated with distinctive clinical and biologic features; however, true lineage-specific treatments have yet to be identified. Recent trials have shown promising results for patients with advanced T-cell malignancies given novel treatment regimens of rotating myelosuppressive agents. Objectives: To evaluate the response of children with advanced stage lymphoblastic lymphoma (T-NHL) and T-cell acute lymphoblastic lymphoma (T-ALL) to high dose methotrexate (HDMTX) (5gm/m2) and cranial radiation (1800 cGy). Estimates of complete response rate (CRR), disease free survival (DFS), event-free survival (EFS), and overall survival (OS) will be analyzed. The administered protocol was modeled after the POG 9404 study, Arm IV, to assess its effectiveness in a developing country's patient population. Methodology: The regimen included 4 doses of HDMTX (5gm/m2) plus leucovorin rescue, given at weeks 4,7, 10, and 13 of therapy. An intensive anthracycline based multidrug regimen (vincristine, doxorubicin, prednisone, methotrexate, and mercaptopurine) combined with high dose asparginase consolidation (25.000 IU/m2) was added by intramuscular injection weekly for 20 weeks starting at week 7. Extended intrathecal chemotherapy (methotrexate and cytarabine) was given as CNS prophylaxis throughout different phases of treatment in addition to central nervous system (CNS) irradiation (1800 cGy) to the brain and meninges given to all patients beginning at week 22. Results: 105 patients with newly diagnosed T-Cell lymphoid malignancy presenting to the department of Pediatric Oncology at the National Cancer Institute, Cairo University between November 1st 2004 and August 1st 2008, were considered eligible for the study and enrolled. Sample population had a mean age of 9.75 years (2–18 years) comprised of 72 (68.6%) T-ALL and 33 (31.4%) T-NHL (stage III & IV) subtypes. All patients were started on the novel regimen as described. 94 cases (89.5%) achieved complete remission post induction therapy. At the conclusion of our follow-up period (6–48 months, median 24 months), 58/105 cases (55.2%) maintained complete remission (CR). Three year disease free survival (DFS) was 47.1±8.6% and 93.3±6.4% for T-Cell ALL and NHL groups, respectively (Fig 1). Three year estimated free survival (EFS) was 48.5±6.2% and 59.2 ±9.2% in T- ALL and T-NHL groups, respectively (Fig 2). 22/105 (20.9%) cases relapsed with classification including nodal relapse in 4 cases, hematological relapse (HR) in 3 cases, CNS relapse in 12 cases, both CNS and HR relapse in 2 cases and both hematological and testicular relapse in 1 case. CNS relapse was the most frequent occurrence, recorded in 14 cases (13.3%), 13 cases for T-ALL and 1 case for T-NHL. Time to relapse ranged between 3 months and 24 months, with 12 cases occurring early in the maintenance phase after cranial irradiation and 2 cases occurring early in consolidation phase before cranial prophylaxis. 6/105 (5.7%) cases failed induction, incorrect diagnoses was found in 2 (1.9%) of those cases. 12/105 (11.4%) patients died during active treatment with mortality equally distributed amongst each phase of therapy. Most common cause of death was sepsis in febrile neutropenic patients 8/105 (7.6%). 6/105 (5.7%) cases were lost to follow up. Toxicities were tolerable in most cases; however, 1 case (1.1%) developed toxicity not amenable to HDMTX. No secondary malignancies were found and no patients underwent bone marrow transplantation (BMT) during the follow up period. Isolated relapse in sanctuary sites was not effectively prevented in this study. Both CNS prophylaxis and CNS directed therapy were administered through extended intrathecal chemotherapy, high dose methotrexate and cranial irradiation. Conclusions: Superior response to extended intrathecal chemotherapy, high dose methotrexate and cranial irradiation was achieved in the T-NHL group compared to the T-ALL group, without significant P value. T-ALL has more significant risk of induction failure (3 of 4 resistant cases), early relapse (<18 months from diagnosis), and isolated CNS relapse when compared to T-NHL. Further studies must be done to delineate the role of CNS directed therapy in improving outcomes for T-cell lymphoid malignancies. Disclosures: No relevant conflicts of interest to declare." @default.
• W2554054155 created "2016-11-30" @default.
• W2554054155 creator A5002444356 @default.
• W2554054155 creator A5006023313 @default.
• W2554054155 creator A5043706544 @default.
• W2554054155 creator A5062423245 @default.
• W2554054155 creator A5072445449 @default.
• W2554054155 creator A5080761329 @default.
• W2554054155 creator A5089622651 @default.
• W2554054155 date "2012-11-16" @default.
• W2554054155 modified "2023-09-28" @default.
• W2554054155 title "Role of High Dose Methotrexate with Cranial Irradiation for Pediatric T-Cell Lymphoid Malignancies" @default.
• W2554054155 doi "https://doi.org/10.1182/blood.v120.21.4310.4310" @default.
• W2554054155 hasPublicationYear "2012" @default.
• W2554054155 type Work @default.
• W2554054155 sameAs 2554054155 @default.
• W2554054155 citedByCount "0" @default.
• W2554054155 crossrefType "journal-article" @default.
• W2554054155 hasAuthorship W2554054155A5002444356 @default.
• W2554054155 hasAuthorship W2554054155A5006023313 @default.
• W2554054155 hasAuthorship W2554054155A5043706544 @default.
• W2554054155 hasAuthorship W2554054155A5062423245 @default.
• W2554054155 hasAuthorship W2554054155A5072445449 @default.
• W2554054155 hasAuthorship W2554054155A5080761329 @default.
• W2554054155 hasAuthorship W2554054155A5089622651 @default.
• W2554054155 hasConcept C126322002 @default.
• W2554054155 hasConcept C141071460 @default.
• W2554054155 hasConcept C143998085 @default.
• W2554054155 hasConcept C203014093 @default.
• W2554054155 hasConcept C2776090121 @default.
• W2554054155 hasConcept C2776694085 @default.
• W2554054155 hasConcept C2776755627 @default.
• W2554054155 hasConcept C2777478502 @default.
• W2554054155 hasConcept C2778041864 @default.
• W2554054155 hasConcept C2778720950 @default.
• W2554054155 hasConcept C2779338263 @default.
• W2554054155 hasConcept C2779429289 @default.
• W2554054155 hasConcept C2781059491 @default.
• W2554054155 hasConcept C2781413609 @default.
• W2554054155 hasConcept C2908647359 @default.
• W2554054155 hasConcept C71924100 @default.
• W2554054155 hasConcept C8891405 @default.
• W2554054155 hasConcept C90924648 @default.
• W2554054155 hasConcept C99454951 @default.
• W2554054155 hasConceptScore W2554054155C126322002 @default.
• W2554054155 hasConceptScore W2554054155C141071460 @default.
• W2554054155 hasConceptScore W2554054155C143998085 @default.
• W2554054155 hasConceptScore W2554054155C203014093 @default.
• W2554054155 hasConceptScore W2554054155C2776090121 @default.
• W2554054155 hasConceptScore W2554054155C2776694085 @default.
• W2554054155 hasConceptScore W2554054155C2776755627 @default.
• W2554054155 hasConceptScore W2554054155C2777478502 @default.
• W2554054155 hasConceptScore W2554054155C2778041864 @default.
• W2554054155 hasConceptScore W2554054155C2778720950 @default.
• W2554054155 hasConceptScore W2554054155C2779338263 @default.
• W2554054155 hasConceptScore W2554054155C2779429289 @default.
• W2554054155 hasConceptScore W2554054155C2781059491 @default.
• W2554054155 hasConceptScore W2554054155C2781413609 @default.
• W2554054155 hasConceptScore W2554054155C2908647359 @default.
• W2554054155 hasConceptScore W2554054155C71924100 @default.
• W2554054155 hasConceptScore W2554054155C8891405 @default.
• W2554054155 hasConceptScore W2554054155C90924648 @default.
• W2554054155 hasConceptScore W2554054155C99454951 @default.
• W2554054155 hasLocation W25540541551 @default.
• W2554054155 hasOpenAccess W2554054155 @default.
• W2554054155 hasPrimaryLocation W25540541551 @default.
• W2554054155 hasRelatedWork W2000417340 @default.
• W2554054155 hasRelatedWork W2118317949 @default.
• W2554054155 hasRelatedWork W2213539131 @default.
• W2554054155 hasRelatedWork W2285218518 @default.
• W2554054155 hasRelatedWork W2397846388 @default.
• W2554054155 hasRelatedWork W2473222514 @default.
• W2554054155 hasRelatedWork W2529155841 @default.
• W2554054155 hasRelatedWork W2554448427 @default.
• W2554054155 hasRelatedWork W2563245602 @default.
• W2554054155 hasRelatedWork W2565395380 @default.
• W2554054155 hasRelatedWork W2566033835 @default.
• W2554054155 hasRelatedWork W2580026576 @default.
• W2554054155 hasRelatedWork W2586346707 @default.
• W2554054155 hasRelatedWork W2588239065 @default.
• W2554054155 hasRelatedWork W2594226348 @default.
• W2554054155 hasRelatedWork W2674675 @default.
• W2554054155 hasRelatedWork W2773247154 @default.
• W2554054155 hasRelatedWork W2885582219 @default.
• W2554054155 hasRelatedWork W2987993711 @default.
• W2554054155 hasRelatedWork W3013131376 @default.
• W2554054155 isParatext "false" @default.
• W2554054155 isRetracted "false" @default.
• W2554054155 magId "2554054155" @default.
• W2554054155 workType "article" @default.